This week in drug discovery (16-20 October)  

News round-up for 16-20 October by DDW Digital Content Editor Diana Spencer.

To celebrate DDW’s first Turning Science into Business Summit on ‘Cancer research opportunities and advances’, the news round-up this week highlights the latest developments in oncology drug discovery.

The top stories:

DDW Cancer Research Summit: Strategies to get to market faster

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will feature experts and thought leaders in cancer research, precision medicine and immunotherapy.

Orphan designated precision drug approved in US for NSCLC

The US Food and Drug Administration (FDA) has approved orphan drug encorafenib (Braftovi) with binimetinib (Mektovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.

CAR T therapy successfully treats solid tumours in China

CARsgen has published evidence of over seven years of disease-free survival in advanced hepatocellular carcinoma (HCC) following treatment with its CAR-GPC3 T cell therapy.

Researchers reverse prostate cancer drug resistance

Prostate cancer’s resistance to treatment can be reversed in some patients by stopping hijacked white blood cells from being ‘pulled into’ tumours, according to new research published in Nature.

Paediatric models for preclinical testing of oncology drugs

The US Food and Drug Administration’s (FDA) Research to Accelerate Cures and Equity (RACE) for Children Act now requires all oncology drugs to be tested for paediatric indications ahead of approval.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free